The government has issued an advisory to all the marketers of oral emergency contraceptive pills (ECP) asking them not to advertise the product.
"Since drug advertising is not permitted under the existing rule, we have sent an advisory to all pharmaceutical companies making ECPs, asking them not to advertise their products through mass media," a source in the Health Ministry told PTI on condition of anonymity.
ECP drugs are to be taken within 72 hours of unprotected sex to avoid pregnancy. Emergency contraceptive pills are not scheduled drugs and can thus be bought over-the-counter, that is to say, without a prescription.
According to the information available, though around 15 companies are now producing ECPs in the country, Piramal Healthcare, Morepen, and Mankind together control over 80 per cent share in the segment.
The national health regulator Drug Controller General of India (DCGI) had earlier this year withdrawn the permission to advertise ECPs through print and electronic media as the ads did not convey the fact that the pills were to be consumed only in case of emergency.
But later, the Health Ministry had permitted it on condition that such ads should make the consumer aware of the side-effects. But recently the DCGI sent notices to three drug makers for showing the ads without addressing the concerns raised by the government.
"The three companies have been asked to respond to the notice within 14 days, failing which the DCGI would may take action against them," the source said.
The technical advisory body for drugs had also decided to frame guidelines on ads of ECPs following reports of side- effects in some cases due to indiscriminate use.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
